Three interlocking studies conducted by researchers at the UCLA Semel Institute conclude that combining two standard medications could lead to greater clinical improvements for children with attention-deficit/hyperactivity disorder (ADHD) than either ADHD therapy alone. Their research sample includes children and adolescents 7-14 years of age with and without ADHD. The studies examine the effects of combining two standard medications, d-methylphenidate (Focalin) and guanfacineon (Intuniv), on clinical, cognitive, and brain activity measures. Results showed consistent added benefits for the combined therapy over the two single treatments, especially for symptoms of inattention, and more global response indices. The rate of good clinical response went up from 62-63% in the single drug therapy to 75% in the combined therapy.